TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
TScan Therapeutics announced an upcoming poster presentation at the ASGCT 29th Annual Meeting featuring their novel CD45-targeted TCR-T cell therapies aimed at eliminating residual disease and preventing relapse post allogeneic hematopoietic cell transplantation in cancer patients. The data will be publicly available post-presentation, highlighting…